SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing massive trading volume and a significant surge as investors react to a de-risking FDA update for its ANKTIVA bladder cancer application, which importantly does not require new clinical trials. This news, coupled with recent international approvals and high short interest, has ignited widespread community discussion about a potential short and gamma squeeze. The intense momentum highlights a fervent belief in the drug's long-term potential as a cancer treatment, driving bullish sentiment against a backdrop of active short positions.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is currently trending due to its recent award of a prime contract position on the U.S. Missile Defense Agency's SHIELD program, significantly bolstering its standing in government AI data training. The community is highly bullish on this development, anticipating a major breakout, potential short squeeze, and further expansion into defense and sovereign AI markets, with many viewing the company as undervalued.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to compelling positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, showcasing strong efficacy in treatment-resistant patients and a favorable safety profile. The community is buzzing about its "best-in-class" potential in a massive market and a possible short squeeze, with many anticipating significant upside or a partnership. Despite the early stage of development, the innovative mechanism is driving substantial investor conversation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to heightened global market uncertainty, fueled by renewed tariff threats against European nations and the ongoing Greenland situation. The community is sharply divided, with some anticipating a familiar "buy the dip" opportunity for the tech-heavy index, while others fear a more sustained market correction if trade tensions further escalate.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a significant licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as crucial validation for its non-mRNA technology. This development is intensifying community discussions about the stock's high short interest and potential for a squeeze, alongside ongoing pressure from an activist investor for management to expedite further partnerships and unlock core asset value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is capturing significant attention following multiple analyst upgrades and reports of a substantial U.S. defense contract under the SHIELD program, fueling strong bullish sentiment. The community is actively discussing the stock's ability to maintain its upward momentum against price resistance ahead of its highly anticipated earnings report, with many expecting positive developments from its server CPU demand and foundry initiatives.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed following its announcement of a record date for a digital token initiative, with many anticipating a short squeeze and other upcoming catalysts. This drives significant polarization, as some investors see substantial upside from loyalist support, while others view it as a highly speculative, politically-charged stock susceptible to market volatility and dilution. The stock remains a key talking point, reflecting the strong intersection of media, branding, and political narratives in its trading dynamics.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as regulatory developments create a mixed outlook: a Massachusetts judge issued a preliminary injunction against prediction market Kalshi, a move seen as highly favorable for traditional sportsbooks. This positive catalyst is juxtaposed with the NCAA's call for a federal halt on college sports betting, intensifying investor debate around regulatory impacts and the rising competition from alternative betting platforms. Community sentiment is also weighing recent analyst upgrades and an increased share buyback authorization, leading to notable stock volatility.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group (TWG) is seeing significant conversation following its announced acquisition of a wine trading business valued at $125 million, to be paid in newly issued shares. This strategic expansion into luxury wine has ignited strong community debate, with investors split between concerns over the share dilution at $7.00 per share and those enthusiastically accumulating the stock on the belief of a future rebound. The intense volatility reflects the mixed sentiment surrounding this low-float entity.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing significant momentum, driven by a recent product innovation award and confirmed ongoing work with Celestial AI, now part of Marvell. The community is highly engaged, actively discussing the company's patented Optical Interposer platform as a crucial solution for AI and data center optical interconnects, which many believe positions the stock for a substantial re-rating. Anticipation is building for further announcements and a potential short squeeze as the market increasingly recognizes its technological advantages and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise.</li><li>BioAtla retains majority ownership of Oz-V, keeping 65% control across solid tumor indications after the transaction closes.</li><li>Phase 3 enrollment is expected to begin in early 2026.</li></ul>Shares of BioAtla Inc. (BCAB) slipped nearly 4% in premarket trading on Wednesday after early gains faded, as investors weighed the structure of the company’s $40 million special purpose vehicle (SPV) financing to advance its lead cancer program.<h2 class="st-heading-2">SPV Deal Funds Late-Stage Trial</h2>BioAtla said the SPV transaction with GATC Health Corp. is designed to fund a registrational Phase 3 trial of ozuriftamab vedotin (Oz-V) in patients whose oropharyngeal cancer has progressed after prior treatments.&nbsp;The company will receive an initial $5 million to support general operations and trial expenses, with the remaining $35 million expected to close in the first quarter of 2026 as the study begins.Following completion, BioAtla will retain 65% ownership of Oz-V across all solid tumor indications, while the SPV, backed by Inversagen AI LLC, will hold the remaining 35%.<h2 class="st-heading-2">Investor Focus On Structure</h2>The single-asset SPV approach allows BioAtla to fund a pivotal trial without a broader equity raise, but the structure appeared to draw a cautious response from investors after the initial premarket rally. Under the arrangement, the SPV will share in future development and commercialization economics for Oz-V.<h2 class="st-heading-2">Phase 3 Path&nbsp;</h2>BioAtla will lead execution of the Phase 3 study, with patient enrollment expected to begin in early 2026.&nbsp;The company said the trial is intended to support a potential accelerated approval pathway in the U.S. Oz-V has received Fast Track designation from the FDA for recurrent or metastatic squamous cell carcinoma of the head and neck.<h2 class="st-heading-2">BioAtla Retains Lead Role On Oz-V</h2>The company said the financing provides a near-term path to advance Oz-V while preserving majority ownership, and noted ongoing discussions around expanding the drug’s use into other HPV-positive solid tumors, including cervical cancer.&nbsp;BioAtla and GATC Health also expect to collaborate with Inversagen AI on additional research tied to senescence and longevity technologies, with BioAtla retaining rights for cancer applications.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for BioAtla was ‘bearish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:973/141;" src="https://news.stocktwits-cdn.com/bcab_ss_png_1ab7393b71.webp" alt="bcab ss.png" width="973" height="141"><figcaption>BCAB sentiment and message volume as of December 31| Source: Stocktwits</figcaption></figure>One user said the market had yet to fully price in the $40 million upfront component of the deal.<stembedurl>https://stocktwits.com/BiotechValues/message/640486061</stembedurl>Another user said the deal fell short of a true global license agreement, pointing instead to the SPV structure and its terms.<stembedurl>https://stocktwits.com/SDBiotechInvestor/message/640485518</stembedurl><a href="https://stocktwits.com/symbol/BCAB">BioAtla’s stock</a> has risen 21% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAtla logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial

The company disclosed the terms and timeline of an SPV arrangement tied to its Oz-V development program.

Equity

Big short fame Michael Burry-run Scion Asset Management’s September quarter 13F <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1649339/000090514824003106/xslForm13F_X02/informationtable.xml">report</a> filed late Thursday showed increased exposure to its China stock holdings Alibaba Group Holding Ltd. (<a class="mention" data-mention="$BABA" data-symbol-id="BABA" href="https://stocktwits.com/symbol/BABA" target="_blank">$BABA</a>), Baidu, Inc. (<a class="mention" data-mention="$BIDU" data-symbol-id="BIDU" href="https://stocktwits.com/symbol/BIDU" target="_blank">$BIDU</a>) and JD.com. Inc. (<a class="mention" data-mention="$JD" data-symbol-id="JD" href="https://stocktwits.com/symbol/JD" target="_blank">$JD</a>). The hedge-fund manager, however, covered much of his positions in these stocks with put options.&nbsp;Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.At the end of the third quarter, Scion held 200,000 Alibaba ADRs valued at $21.22 million, up from 155,000 ADRs worth $11.16 million at the end of the second quarter.He hedged his Alibaba bet by buying put options on 168,900 ADRs. This strategy insulates him against any potential drop in Alibaba shares.&nbsp;Alibaba shares have rebounded nicely this year amid China’s concerted efforts to stimulate domestic growth. The e-commerce giant is scheduled to report its second-quarter results before the market opens on Friday.Burry’s firm increased its Baidu holding from 75,000 ADRs, valued at $6.49 million, to 125,000 ADRs worth $13.16 million. It also bought put options on 83,000 Baidu ADRs.The firm loaded up ADRs of Alibaba’s peer JD, increasing its stake in the company from 250,000 ADRs to 500,000 ADRs. The value of JD,com holdings swelled from $6.46 million to $20 million. Bury also bought puts on JD.com for 500,000 in underlying shares.On the other hand, Burry halved RealReal, Inc. (<a class="mention" data-mention="$REAL" data-symbol-id="REAL" href="https://stocktwits.com/symbol/REAL" target="_blank">$REAL</a>) holdings from 1 million shares to 500,00 shares. It also significantly cut its stake in&nbsp;American Coastal Insurance Corporation (<a class="mention" data-mention="$ACIC" data-symbol-id="ACIC" href="https://stocktwits.com/symbol/ACIC" target="_blank">$ACIC</a>) from 251,892 to 100,000.Scion fully cashed out of oncology-focused biotech BioAtla, Inc. (<a class="mention" data-mention="$BCAB" data-symbol-id="BCAB" href="https://stocktwits.com/symbol/BCAB" target="_blank">$BCAB</a>) and office real estate investment trust Hudson Pacific Properties, Inc. (<a class="mention" data-mention="$HPP" data-symbol-id="HPP" href="https://stocktwits.com/symbol/HPP" target="_blank">$HPP</a>).On Stocktwits, sentiment towards Burry’s China holdings is muted.&nbsp;Sentiment toward Alibaba was 'neutral' on Stocktwits platform, although improving from a 'bearish' stance a day ago.<figure class="image"><a href="https://stocktwits.com/symbol/BABA"><img style="aspect-ratio:632/133;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/baba_bury_sentiment_76d1568b0e.png" alt="baba-bury-sentiment.png" width="632" height="133"></a><figcaption>BABA sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>&nbsp;JD.com elicited 'bearish sentiment' (36/100) from the retail, although message activity remained 'extremely high,' possibly due to the earnings report released Thursday.<figure class="image"><a href="https://stocktwits.com/symbol/JD"><img style="aspect-ratio:630/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/jd_sentiment_cffa43fe76.png" alt="jd-sentiment.png" width="630" height="135"></a><figcaption>JD sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Baidu did not fare any better, with the retail mood 'bearish' (45/100) on Stocktwits, although message volume, a proxy for activity, was 'high.'<figure class="image"><a href="https://stocktwits.com/symbol/BIDU"><img style="aspect-ratio:632/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bidu_sentiment_fb301f5932.png" alt="bidu-sentiment.png" width="632" height="140"></a><figcaption>BIDU sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 4:06 am ET, Alibaba shares eased 0.63% to $90.01, while JD.com climbed 1.83% to $33.96 and Baidu gained 1.18% to $85.05.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-s-berkshire-initiates-positions-in-domino-s-pizza-pool-corp-does-retail-share-the-sentiment/cJ4F7DqRfp">Warren Buffett’s Berkshire Initiates Positions In Domino’s Pizza, Pool Corp: Does Retail Share The Sentiment?</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Chinese stocks are seeing green shoots of recovery amid stimulus measures to reinvigorate growth.

Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism

Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Current Price	$0.325
Prev Close	$0.3222
Open	$0.34
Dividend Yield	0.00%
50-Day Moving Average	$0.7099
Beta	1.84
Avg. Volume	1.54M
PE Ratio	-0.28

52-Week High	$1.43
52-Week Low	$0.24
Market Capitalization	$20.63M
EPS (Annual)	-$1.44
Price to Book	-0.61
Revenue Per Employee	$144,736.84
Enterprise Value/EBITDA	N/A

BCAB
BioAtla Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAB News

BCABBioAtla Inc